Welcome
Welcome to this week's edition! We apply fundamental price-valuation methods together with our proprietary efficiency formulas to evaluate how well each stock works for capital. Using AI as a tool we deliver clear, fact-checked insights into companies across sectors. Each issue highlights valuation ranges, risk profiles, and efficiency ratings so you can navigate the market with discipline and precision.
What You'll Get Every Week
Macro Trends: A snapshot of big-picture economic signals and how they impact AI stocks.
How to Understand Our Efficiency Score: A simple guide to rating stock trades based on risk and reward.
Stock Evaluations: In-depth looks at 4-5 promising equities, with stats, stories, catalysts, and action plans.
Quick Portfolio Overview: A handy table summarizing the stocks for easy comparison.
Macro Trends
The U.S. economy is showing resilience in mid-2025, with growth picking up but some headwinds from potential rate adjustments and trade policies. GDP grew at a 3.3% annual rate in Q2. The Fed funds target range is 4.25%–4.50%; the 10-year is around 4.2%. The latest CPI (July) is 2.7% YoY; August CPI will be released Sep 11, 2025, with consensus expectation around 2.8%. Credit spreads are tight (HY ~2.9%, BBB ~1.0%). Recent trade actions raise tariffs on China-origin semiconductors to 50% by 2025 and EVs to 100%; any broader 100% semiconductor tariff is a proposal, not current policy.
Unemployment held at 4.3% in August, the highest since 2021, signaling a softening job market that could prompt Fed action. The Federal Reserve held rates steady at 4.25%-4.50%, with the effective rate at 4.33%, but markets anticipate quarter-point cuts in September and December amid labor weakness. The yield curve is normalizing slowly, with the 10-year Treasury around 4.2%. Credit spreads have tightened modestly for high-yield (OAS ~2.86%) and BBB (~1.00%), reflecting easing hopes but with some volatility.
Overall, these trends favor stocks with strong balance sheets: potential rate cuts could boost tech R&D investment, but tariffs might squeeze margins for import-heavy firms. Consensus GDP forecasts range from 0.8%-2% for full-year 2025, suggesting Q2 strength may not persist. Here's a quick table of key indicators:
Indicator | Current Level (Sep 2025) | Trend | Impact on AI Stocks |
|---|---|---|---|
GDP Growth | 3.3% (Q2 annual rate) | Up from Q1 | Positive: Fuels enterprise spending |
Unemployment | ~4.3% (August data) | Up | Neutral: Rate cuts could ease capital costs |
Inflation (CPI) | ~2.7% (July actual); ~2.8% (August expected) | Slightly up | Positive: Reduces input cost pressures |
Fed Funds Rate | 4.25%-4.50% | Steady, cuts expected | Positive: Cheaper funding |
10-Year Yield | ~4.2% | Slightly down | Neutral: Supports valuations but watch inversion |
Credit Spreads | Tightened modestly | Down | Positive: Easier borrowing |
Recent News | Tariffs on China semis to 50% by 2025, EVs to 100%; broader proposals uncertain | Uncertain | Risk: Supply chain disruptions |
This setup suggests steady AI equity performance if growth holds, but watch for tariff escalations that could dent profits.
How to Understand Our Efficiency Score
Our Efficiency Score rates how well a stock or options trade balances expected returns, risks, liquidity, and other factors like volatility and costs. It's based on a 0-10 scale, Higher scores mean better "bang for your buck" in terms of efficient exposure to upside with controlled risks.
Score Range | Rating | What It Means |
|---|---|---|
0-4 | Weak | High risks outweigh rewards; avoid or use sparingly. |
5-6 | Fair | Balanced but room for improvement; suitable for core holdings. |
7-8 | Good | Strong efficiency; great for leveraged plays like options. |
9-10 | Excellent | Top-tier setup; prioritize for portfolio weighting. |
Scores adapt from trade-specific data, favoring equities with net cash and options with good liquidity.
Stock Evaluations
Regeneron Pharmaceuticals (REGN): Biotech Pioneer in Drug Discovery
Key Stats
Q2 2025 revenues: $3.68B (+4% YoY)
Non-GAAP EPS: $12.89 (+12% YoY)
Net cash: ~$14.8B, supporting AI-enhanced R&D
Efficiency Score: Fair (5-6/10 for equity; Good 7-8/10 for LEAPs)
The Story Regeneron is a leading biotech firm using AI to accelerate drug development, especially in eye care (EYLEA) and oncology. Despite competition in retina treatments like Vabysmo, its Dupixent alliance with Sanofi drives double-digit growth. The company boasts a fortress balance sheet with $17.5B in cash against minimal debt, enabling ongoing buybacks and a new dividend. Recent FDA approvals, like Lynozyfic for myeloma, highlight its pipeline strength, though regulatory delays on EYLEA HD extensions pose short-term hurdles. Overall, it's a quality compounder leveraging AI for precision medicine.
What Could Spark a Rise
FDA clarity on EYLEA HD label and syringe in Q4 2025, boosting U.S. sales.
Continued Dupixent growth and oncology expansions amid AI-optimized trials.
Real-world data showing EYLEA HD's edge over competitors.
Action Plan
Price Range | What to Do with Stocks | Options Idea | Max Portfolio Weight |
|---|---|---|---|
≤ $600 | Buy / Accumulate | Buy Dec 2026 600C LEAPs | 5-7% |
$600–$680 | Hold / Add on dips | Hold existing calls | 4-6% |
≥ $700 | Trim / Hedge | Sell covered calls | 3-5% |
Fair Value: $620 (blended); upside ~8% from current ~$573.
Apple (AAPL): Tech Giant Priced for Aggressive Growth
Key Stats
Q3 FY25 net sales: $94.0B (+9.7% YoY)
9M FY25 diluted EPS: $5.62
Net cash: ~$31.3B, fueling AI ecosystem builds
Efficiency Score: Weak (3-4/10 for equity and LEAPs)
The Story Apple dominates consumer tech with iOS, Siri, and hardware like the Vision Pro. Q3 showed solid services growth and iPhone recovery, offset by wearables softness. Massive buybacks ($69B in 9M) and a 0.43% yield underscore capital returns, but high valuations (P/E ~36x) reflect mega-cap premiums. AI platform transitions could drive monetization, though China demand and regulatory risks loom. It's a quality name, but current pricing implies aggressive growth assumptions.
What Could Spark a Rise
Strong AI monetization in upcoming device cycles and services ARPU.
Resolution of China regulatory frictions boosting segment sales.
Positive FX and supply chain stability amid hedging efforts.
Action Plan
Price Range | What to Do with Stocks | Options Idea | Max Portfolio Weight |
|---|---|---|---|
≤ $130 | Buy | Buy longest-dated 2027 LEAPs (verify exact month on your platform) | 8-10% |
$130–$145 | Accumulate | Debit spreads on dips | 6-8% |
$145–$165 | Hold / Neutral | Hold existing | 5-7% |
$165–$180 | Trim / Hedge | Sell covered calls | 4-6% |
≥ $180 | Reduce / Avoid | Avoid new positions | 3-5% |
Fair Value: $155 (blended mid); downside ~35% from current ~$240.
Ralliant Corporation (RAL): Precision Tech Enabler for AI Systems
Key Stats
Q2 revenue: $503.3M; 6M revenue: $985.1M
Q2 diluted EPS: $0.42
Cash: $198.6M; current ratio ~1.59x
Efficiency Score: Fair (5-6/10 for equity; Weak 3-4/10 for LEAPs)
The Story Ralliant, a recent Fortive spin-off, provides precision instruments and sensors critical in manufacturing, defense, and safety. Q2 saw Sensors & Safety Systems shine with $310M sales and strong profits, offsetting Test & Measurement weakness. Post-spin leverage is a watch point, but solid cash flow ($157M in 6M) supports deleveraging. Demand in semis and industrial capex could fuel recovery, making it a cyclical play with mid-teens EV/EBITDA valuation.
What Could Spark a Rise
T&M segment rebound from semi/tools demand.
Successful cost programs and deleveraging post-spin.
New wins in defense and utilities amid program ramps.
Action Plan
Price Range | What to Do with Stocks | Options Idea | Max Portfolio Weight |
|---|---|---|---|
≤ $38 | Buy / Initiate | Buy Jan 2027 ATM calls (if liquidity improves) | 4-6% |
$38–$44 | Accumulate / DRIP equivalent | Hold for depth | 3-5% |
$44–$54 | Neutral | Consider collars if needed | 2-4% |
≥ $54 | Trim / Hedge | Consider collars | 2-4% |
Fair Value: $41–$52; upside ~8% from current ~$43 (to mid-range).
Koninklijke Philips (PHG): Health Tech Innovator with Imaging Focus
Key Stats
Q2 2025 sales: €4.3B
Adj. EBITA margin: 12.4% (+130 bps YoY)
Free cash flow: €230M
Efficiency Score: Fair (6/10 for equity; Poor 2/10 for LEAPs)
The Story Philips advances healthcare technology via imaging, monitoring, and informatics. Q2 orders rose 6%, with margin gains from productivity despite tariffs. Raised FY25 guidance reflects recovery, though China weakness and Respironics legacy persist. AI-enabled tools like enterprise imaging position it for precision medicine growth, backed by a 3.6% yield and €8.4B debt managed through FCF.
What Could Spark a Rise
Hitting 11.3–11.8% Adj. EBITA and €0.2–0.4B FCF targets amid tariff mitigation.
Backlog execution and new deals (e.g., Indonesia MoH) boosting orders.
AI differentiation vs. peers like GEHC, unlocking low-teens multiples.
Action Plan
Price Range | What to Do with Stocks | Options Idea | Max Portfolio Weight |
|---|---|---|---|
≤ $24 | Buy / Accumulate | Avoid until liquidity improves | 5-7% |
$24–$29 | Hold / Add on dips | Debit spreads if spreads tighten | 4-6% |
$29–$33 | Hold / Trim | Covered calls (≤5% spreads) | 3-5% |
≥ $33 | Trim / Hedge | Covered calls (≤5% spreads) | 3-5% |
Fair Value: $26–$33 (mid $30–$31); upside ~9% from current ~$28.
Quick Portfolio Overview
Stock | Ticker | Current Price | Fair Value | Upside Potential | Efficiency Score (Equity) | Efficiency Score (LEAP) |
|---|---|---|---|---|---|---|
Regeneron Pharmaceuticals | REGN | ~$573 | $620 | 8% | Fair | Good |
Apple | AAPL | ~$240 | $155 | -35% (Downside Risk) | Weak | Weak |
Ralliant Corporation | RAL | ~$43 | $41–$52 (mid $46.5) | 8% | Fair | Weak |
Koninklijke Philips | PHG | ~$28 | $26–$33 (mid $30.5) | 9% | Fair | Poor |
Interested in have a company researched for the next newsletter? Send us a suggestion using the button below!
Important Legal Notices and Disclaimers
The information in this newsletter is for informational purposes only and does not constitute investment advice, financial advice, trading advice, or any other sort of advice. Past performance is not indicative of future results. All investments involve risk, including the possible loss of capital. You should do your own research and consult with a qualified financial advisor before making any investment decisions. We are not responsible for any losses incurred based on this content.
Know someone who'd love this? Forward this email or use this website link.